Biblio Discovery — Demo Discovery Service

8 hasil untuk "Daniel Atar"

Menampilkan 1–8 · 0,18 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas

    Daniel Atar; Anna-Sophia Mast; Sophia Scheuermann dkk.

    Biomedicines, Vol. 10 No. 10 · 2022 · Inggris · DOAJ Scopus

    CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T cells. The major cause of death in heavily…

  2. Artikel Jurnal

    Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia

    Anna-Sophia Mast; Daniel Atar; Lara Ruoff dkk.

    OncoImmunology, Vol. 15 No. 1 · 2026 · Inggris · DOAJ Scopus

    Chimeric antigen receptor (CAR) T cell therapy for acute myeloid leukemia (AML) faces critical challenges, including severe on-target off-tumor toxicities, antigen heterogeneity, and primary immune evasion mechanisms. To address these limitations, we previously developed an adapter CAR (AdCAR)…

  3. Artikel Jurnal

    CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome

    Ann‐Christin Pecher; Luca Hensen; Reinhild Klein dkk.

    JAMA · 2023 · Inggris · OpenAlex

    Importance: Autoimmune disorders can affect various organs and if refractory, can be life threatening. Recently, CD19-targeting-chimeric antigen receptor (CAR) T cells were efficacious as an immune suppressive agent in 6 patients with refractory systemic lupus erythematosus and in 1 patient with…

  4. Artikel Jurnal

    GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells

    Christian M. Seitz; Sarah Schroeder; Philipp Knopf dkk.

    OncoImmunology, Vol. 9 No. 1 · 2020 · Inggris · DOAJ Scopus

    Expression of the disialoganglioside GD2 has been identified as a marker antigen associated with a breast cancer stem-like cell (BCSC) phenotype. Here, we report on the evaluation of GD2 as a BCSC-specific target antigen for immunotherapy. GD2 expression was confirmed at variable degree in a set of…

  5. Artikel Jurnal

    Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort

    Martin Ebinger; Rimas J Orentas; Dina Schneider dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 14 No. 5 · 2026 · Inggris · DOAJ Scopus

    Background CD19-directed chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape for pediatric B-cell acute lymphoblastic leukemia (B-ALL), yet relapses driven by antigen escape remain a major limitation. Dual-targeting CAR approaches recognizing CD19 and CD22 have…

  6. Artikel Jurnal

    Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting

    Christian M. Seitz; Joerg Mittelstaet; Daniel Atar dkk.

    OncoImmunology, Vol. 10 No. 1 · 2021 · Inggris · DOAJ Scopus

    Chimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad applicability of CAR-T cell therapies is hampered by limited CAR-T cell versatility and tractability and the lack of exclusive target antigens to discriminate cancerous…

  7. Artikel Jurnal

    Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation

    Amadeus T Heinz; Friso G.J. Calkoen; Alexander Derbich dkk.

    Haematologica, Vol. 108 No. 8 · 2023 · Inggris · DOAJ Scopus

    Therapy-resistant viral reactivations contribute significantly to mortality after hematopoietic stem cell transplantation. Adoptive cellular therapy with virus-specific T cells (VST) has shown efficacy in various single-center trials. However, the scalability of this therapy is hampered by…

  8. Artikel Jurnal

    Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

    Christian Martin Seitz; Tim Flaadt; Markus Mezger dkk.

    Frontiers in Immunology, Vol. 12 · 2021 · Inggris · DOAJ Scopus

    Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The combinatorial therapy of haplo SCT and…